S-3304
DRACPC ID DRACPC0045
Active Ingredients S-3304
Description An orally-agent agent with potential antineoplastic activity. S-3304 inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.
Synonyms MMP Inhibitor S-3304; S-3304
Type Small Molecule
Disease Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer
Classification
MMP inhibitor Amino acid and derivative
Structure Information
Molecular Formula C24H20N2O4S2
Molecular Weight 464.6
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (2R)-3-(1H-indol-3-yl)-2-[[5-[2-(4-methylphenyl)ethynyl]thiophen-2-yl]sulfonylamino]propanoic acid
InChI InChI=1S/C24H20N2O4S2/c1-16-6-8-17(9-7-16)10-11-19-12-13-23(31-19)32(29,30)26-22(24(27)28)14-18-15-25-21-5-3-2-4-20(18)21/h2-9,12-13,15,22,25-26H,14H2,1H3,(H,27,28)/t22-/m1/s1
InChI_Key YWCLDDLVLSQGSZ-JOCHJYFZSA-N
SMILES CC(C=C1)=CC=C1C#CC2=CC=C(S2)S(=O)(N[C@@H](C(O)=O)CC3=CNC4=C3C=CC=C4)=O
External Codes
PubChem CID 10718956
DrugBank Accession Number DB12149
NCI Thesaurus Code C2671
UNII BK459F050X GSRS
CAS 203640-27-1
Drug approval
Drug indication
S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer, and Stage IIIA Non Small Cell Lung Cancer, among others.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00078390 | A Phase I/II Study of the Safety, Pharmacokinetic Interaction and Efficacy of S-3304 in Combination With Standard Therapy in Patients With Locally Advanced Non-small Cell Lung Cancer. | Non Small Cell Lung Cancer; Lung Cancer; Stage IIIA Non Small Cell Lung Cancer; Stage IIIB Non Small Cell Lung Cancer | Phase 1/2 | Treatment |
| NCT00033566 | A Phase I Study of S-3304 in Patients With Solid Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Treatment |
| NCT00033215 | A Phase 1 Study of S-3304 in Patients With Solid Tumors | Solid Tumors | Phase 1 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
